PE44597A1 - Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos - Google Patents

Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos

Info

Publication number
PE44597A1
PE44597A1 PE1996000133A PE00013396A PE44597A1 PE 44597 A1 PE44597 A1 PE 44597A1 PE 1996000133 A PE1996000133 A PE 1996000133A PE 00013396 A PE00013396 A PE 00013396A PE 44597 A1 PE44597 A1 PE 44597A1
Authority
PE
Peru
Prior art keywords
compounds
alkyl
formula
group
benzotiofen
Prior art date
Application number
PE1996000133A
Other languages
English (en)
Inventor
Alan David Palkowitz
Kenneth Jeff Thrasher
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/396,401 external-priority patent/US5510357A/en
Priority claimed from US08/552,890 external-priority patent/US5919800A/en
Priority claimed from US08/552,564 external-priority patent/US5998441A/en
Priority claimed from US08/552,679 external-priority patent/US5856339A/en
Priority claimed from US08/552,565 external-priority patent/US5977093A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE44597A1 publication Critical patent/PE44597A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS TIOFENO DE FORMULA (I), EN DONDE: R1 ES R1a, OH, -O-ALQUILO(C1-C4), -OCOC6H5, -OCO-ALQUILO(C1-C6) o SO2-ALQUILO(C2-C6); R2 ES R2a, R1; R1a ES H, OR7; R2a ES H, HALO, OR8; R6,R7 Y R8 SON GRUPOS PROTECTORES HIDROXI; R9 ES GRUPO SALIENTE, Z-pFENILO-O(CH2)n-R3, Z-pFENILO-OR6; Z ES O o S; R11 NO EXISTE O ES =O. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE OBTENCION, QUE COMPRENDE: (A) OXIDACION DEL ATOMO DE AZUFRE DE UN COMPUESTO DE FORMULA (I), EN EL QUE R1 ES R1a, R2 ES R2a, R11 NO EXISTE Y R9 ES UN GRUPO SALIENTE; (B) POSTERIOR REACCION CON UN GRUPO NUCLEOFILICO R12-pFENILO-O(CH2)n-R3 DONDE R12 ES OH o SH; (C) REDUCCION DEL PRODUCTO DEL PASO (B) PARA DAR UN COMPUESTO DE FORMULA (I), DONDE R9 ES Z-pFENILO-O(CH2)nR3; Y (D) OPCIONAL ELIMINACION DE LOS GRUPOS PROTECTORES HIDROXI, Y FORMACION DE LA SAL. ESTOS COMPUESTOS SON USADOS PARA EL TRATAMIENTO DEL SINDROME POST MENOPAUSICO Y OTROS TRANSTORNOS PATOLOGICOS RELACIONADOS CON LOS ESTROGENOS TALES COMO FIBROSIS UTERINA, ENDOMETROSIS, ENTRE OTROS
PE1996000133A 1995-02-28 1996-02-27 Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos PE44597A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/396,401 US5510357A (en) 1995-02-28 1995-02-28 Benzothiophene compounds as anti-estrogenic agents
US55276095A 1995-11-03 1995-11-03
US08/552,890 US5919800A (en) 1995-02-28 1995-11-03 Benzothiophene compounds, intermediates, compositions, and methods
US08/552,564 US5998441A (en) 1995-02-28 1995-11-03 Benzothiophene compounds, intermediates, compositions, and methods
US08/552,679 US5856339A (en) 1995-02-28 1995-11-03 Benzothiophene compounds, intermediates, compositions, and methods
US08/552,565 US5977093A (en) 1995-02-28 1995-11-03 Benzothiophene compounds, intermediates, compositions, and methods

Publications (1)

Publication Number Publication Date
PE44597A1 true PE44597A1 (es) 1997-10-13

Family

ID=27559919

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000133A PE44597A1 (es) 1995-02-28 1996-02-27 Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos

Country Status (16)

Country Link
EP (2) EP0729956B1 (es)
JP (2) JP3989569B2 (es)
AR (1) AR003930A1 (es)
AT (1) ATE207913T1 (es)
DE (1) DE69616396T2 (es)
DK (1) DK0729956T3 (es)
ES (1) ES2163587T3 (es)
FI (1) FI20095804A (es)
HK (1) HK1013991A1 (es)
IL (7) IL117276A (es)
PE (1) PE44597A1 (es)
PL (1) PL182493B1 (es)
PT (1) PT729956E (es)
SG (2) SG90193A1 (es)
SI (1) SI0729956T1 (es)
UA (1) UA44710C2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL182493B1 (pl) * 1995-02-28 2002-01-31 Lilly Co Eli Nowe pochodne benzotiofenu, nowe związki pośrednie i sposób wytwarzania nowych pochodnych benzotiofenu oraz środek farmaceutyczny
CA2214072C (en) * 1996-08-29 2006-11-14 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods
CA2216592C (en) * 1996-10-24 2006-07-18 Brian Stephen Muehl Benzothiophene compounds, intermediates, compositions, and methods
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
ZA982818B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Prevention of breast cancer using selective estrogen receptor modulators.
ZA982819B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
WO1998055454A2 (en) * 1997-06-05 1998-12-10 Takeda Chemical Industries, Ltd. Benzofurans and benzothophenes as suppressors of neurodegeneration
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6090843A (en) * 1997-08-11 2000-07-18 Eli Lilly And Company Benzothiophenes compounds which have useful pharmaceutical activity
ID24978A (id) * 1997-11-14 2000-08-31 Lilly Co Eli 2-ARYL-3-AROYLBENZO (b) THIOPHENES BERGUNA UNTUK PENGOBATAN SINDROM DEPRIVASI ESTROGEN
US6096781A (en) * 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
HUP0103834A2 (hu) * 1998-06-16 2002-05-29 Eli Lilly And Co. Eljárás az acetil-kolin-szint növelésére
CN1305377A (zh) 1998-06-16 2001-07-25 伊莱利利公司 提高乙酰胆碱水平的方法
US6087378A (en) * 1998-10-13 2000-07-11 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
PT1140888E (pt) * 1998-12-14 2003-09-30 Vertex Pharma San Diego Llc Sensores opticos moleculares para a actividade do citocromo p450
AU3964400A (en) * 1999-04-06 2000-10-23 Akzo Nobel N.V. Selective estrogenic compounds
DE60005693T2 (de) * 1999-07-29 2004-07-29 Eli Lilly And Co., Indianapolis Eine kristalline form von 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen-hydrochlorid
EP1204656A2 (en) * 1999-07-29 2002-05-15 Eli Lilly And Company A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride
ATE368046T1 (de) * 2000-03-10 2007-08-15 Univ Baylor Tubulin bindende liganden
EP1757291A3 (en) * 2000-05-08 2009-07-15 Eli Lilly & Company Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
WO2001085147A2 (en) * 2000-05-08 2001-11-15 Eli Lilly And Company STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE AND SALTS THEREOF
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
KR20030037690A (ko) * 2000-10-20 2003-05-14 일라이 릴리 앤드 캄파니 6-히드록시-3-(4-[2-(피페리딘-1-일)에톡시]페녹시)-2-(4-메톡시페닐)벤조[ｂ]티오펜 히드로클로라이드의 신규 결정형
JP4656939B2 (ja) 2002-07-22 2011-03-23 イーライ リリー アンド カンパニー フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター
CN1548434B (zh) * 2003-05-16 2010-07-28 中国科学院上海药物研究所 一类苯并噻吩类化合物、及制备和它的医药用途
EP1709022A1 (en) * 2004-01-22 2006-10-11 Eli Lilly And Company Selective estrogen receptor modulators
WO2006088648A1 (en) * 2005-02-11 2006-08-24 Eli Lilly And Company Compositions and methods for treating dyslipidemia
FR2913017A1 (fr) * 2007-02-23 2008-08-29 Cerep Sa Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire
US8124776B2 (en) 2007-03-16 2012-02-28 Eli Lilly And Company Process and intermediates for preparing arzoxifene
SG11201505697VA (en) 2013-02-19 2015-09-29 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
HUE056957T2 (hu) * 2014-08-29 2022-04-28 Chdi Foundation Inc Próbák huntingtin fehérjét megjelenítõ képalkotásra

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1300575B (de) * 1965-05-21 1969-08-07 Bristol Myers Co Benzo[b]thiophene
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
FR2447914A1 (fr) * 1979-02-05 1980-08-29 Sanofi Sa Nouveaux benzothiophenes, leurs procedes de preparation et leur application notamment comme hypolipemiants et hypocholesterolemiants
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
IL65379A0 (en) * 1981-04-03 1982-05-31 Lilly Co Eli Process for preparing acylated benzothiophenes
DE4117512A1 (de) * 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
CA2145614A1 (en) * 1994-03-31 1995-10-01 Jeffrey A. Dodge Intermediates and processes for preparing benzothiophene compounds
US5484798A (en) * 1994-09-20 1996-01-16 Eli Lilly And Company Benzothiopene compounds, compositions, and method of inhibiting restenosis
PL182493B1 (pl) * 1995-02-28 2002-01-31 Lilly Co Eli Nowe pochodne benzotiofenu, nowe związki pośrednie i sposób wytwarzania nowych pochodnych benzotiofenu oraz środek farmaceutyczny

Also Published As

Publication number Publication date
DE69616396T2 (de) 2002-07-11
IL132954A0 (en) 2001-03-19
UA44710C2 (uk) 2002-03-15
JPH09183776A (ja) 1997-07-15
ATE207913T1 (de) 2001-11-15
ES2163587T3 (es) 2002-02-01
EP0729956B1 (en) 2001-10-31
IL132953A (en) 2002-02-10
IL117276A (en) 2001-10-31
DE69616396D1 (de) 2001-12-06
HK1013991A1 (en) 1999-09-17
DK0729956T3 (da) 2001-11-26
IL132954A (en) 2002-02-10
IL117276A0 (en) 1996-06-18
JP2007238626A (ja) 2007-09-20
PT729956E (pt) 2002-03-28
FI20095804A (fi) 2009-07-23
PL182493B1 (pl) 2002-01-31
SI0729956T1 (en) 2002-04-30
AR003930A1 (es) 1998-09-30
SG90193A1 (en) 2002-07-23
PL312955A1 (en) 1996-09-02
JP3989569B2 (ja) 2007-10-10
SG64896A1 (en) 1999-05-25
EP0729956A1 (en) 1996-09-04
IL132952A0 (en) 2001-03-19
EP1113013A1 (en) 2001-07-04
IL132952A (en) 2002-02-10
IL132953A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
PE44597A1 (es) Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos
PE28497A1 (es) Compuestos de naftilo, intermedios, composiciones y procedimientos
TR200000673T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
TR200000670T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
AP1895A (en) Novel benzoimidazole derivatives useful as antiproliferative agents.
HUP9901074A2 (hu) Tetrahidropirán és tetrahidrotiopirán aminosavak és ezeket tartalmazó gyógyszerkészítmények
ES2064310T3 (es) Procedimiento para preparar compuestos de imidazopiridina.
ECSP056128A (es) Fluoro y trifluoroalquil que contienen inhibidores de producción de beta amiloide de sulfonamida heterociclico y derivados del mismo
DK0974580T3 (da) Omega-Cycloalkylprostaglandin E1 derivativer
ES2061077T3 (es) Metodo para producir un producto intermedio para la preparacion de promedicamentos.
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
ATE150301T1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische zusammensetzungen davon zur prävention oder behandlung von herzerkrankungen
CA2412932A1 (en) Pleuromutilin derivatives having antibacterial activity
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
ATE243215T1 (de) Neue 2-decarboxy-2-phosphinico prostaglandin f analoge
BR0008776A (pt) Análogos de prostaglandinas fp-seletivosinsaturados c16
ES2188743T3 (es) Compuestos de acido pirrolidinilhidroxamico y procedimiento de produccion de los mismos.
KR950701909A (ko) 신규한 비타민D 동족체(Novel vitamin D analogues)
HUT65913A (en) Ocular hypotensive 2-decarboxyl-2-acylthioalkyl prostaglandin derivatives, pharmaceutical comp. cont. them and method to prepare them
PT95990A (pt) Processo para a preparacao de novos derivados do tiofeno
ES535411A0 (es) Procedimiento para preparar nuevos derivados del acido 4-fenil-4-oxo-buten-2-oico
FR2361326A1 (fr) Derives de cyclohexane utiles comme agents odoriferants
ATE98230T1 (de) Indolderivate.
CA2324590A1 (en) C11 oxymyl and hydroxylamino prostaglandins useful as fp agonists
ES2055429T3 (es) Proceso para preparar derivados del acido 9-alfa-hidroxi-3-oxo-4,24(25)-estigmastadieno-26-oico, asi como composiciones farmaceuticas que contienen estos compuestos.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed